JP2003513942A - インビボ遺伝子送達による心血管疾患を処理するための技術および組成物 - Google Patents

インビボ遺伝子送達による心血管疾患を処理するための技術および組成物

Info

Publication number
JP2003513942A
JP2003513942A JP2001536204A JP2001536204A JP2003513942A JP 2003513942 A JP2003513942 A JP 2003513942A JP 2001536204 A JP2001536204 A JP 2001536204A JP 2001536204 A JP2001536204 A JP 2001536204A JP 2003513942 A JP2003513942 A JP 2003513942A
Authority
JP
Japan
Prior art keywords
vector
growth factor
peptide
angiogenic
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001536204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003513942A5 (https=
Inventor
エイチ． カーク ハンモンド，
フランク ジェイ． ジョルダノ，
ウォルフガング エイチ． ディルマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2003513942A publication Critical patent/JP2003513942A/ja
Publication of JP2003513942A5 publication Critical patent/JP2003513942A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001536204A 1999-11-05 2000-11-03 インビボ遺伝子送達による心血管疾患を処理するための技術および組成物 Pending JP2003513942A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43515699A 1999-11-05 1999-11-05
US09/435,156 1999-11-05
US60908000A 2000-06-30 2000-06-30
US09/609,080 2000-06-30
PCT/US2000/030345 WO2001034208A1 (en) 1999-11-05 2000-11-03 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery

Publications (2)

Publication Number Publication Date
JP2003513942A true JP2003513942A (ja) 2003-04-15
JP2003513942A5 JP2003513942A5 (https=) 2007-12-20

Family

ID=27030448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001536204A Pending JP2003513942A (ja) 1999-11-05 2000-11-03 インビボ遺伝子送達による心血管疾患を処理するための技術および組成物

Country Status (10)

Country Link
EP (1) EP1225921A1 (https=)
JP (1) JP2003513942A (https=)
KR (1) KR20020049031A (https=)
CN (1) CN1433325A (https=)
AU (1) AU784392B2 (https=)
CA (1) CA2389524A1 (https=)
EA (1) EA008538B1 (https=)
HK (1) HK1048593A1 (https=)
NZ (1) NZ546670A (https=)
WO (1) WO2001034208A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544698A (ja) * 2006-07-25 2009-12-17 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
CN114173863A (zh) * 2019-08-07 2022-03-11 西北大学 用于在心脏中基因递送的材料和方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034208A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
EP2559698B1 (en) * 2007-08-24 2014-11-12 Julius-Maximilians-Universität Würzburg Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies
JP5579164B2 (ja) 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
WO2010078624A1 (en) * 2009-01-07 2010-07-15 Vegenics Limited Materials and methods for the treatment of hypertension
KR101006106B1 (ko) * 2009-06-04 2011-01-07 김현태 전·자기장 차단 전열선
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
CA2864100A1 (en) 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
WO2013184782A2 (en) 2012-06-05 2013-12-12 Muffin Incorporated Catheter systems and methods useful for cell therapy
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
US20210393805A1 (en) * 2018-05-16 2021-12-23 University Of Massachusetts Perfusion-based delivery of recombinant aav vectors for expression of secreted proteins
KR20210027493A (ko) 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050079A2 (en) * 1997-05-06 1998-11-12 The Regents Of The University Of California Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
WO1999040945A2 (en) * 1998-02-11 1999-08-19 The Regents Of The University Of California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034208A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EA001616B1 (ru) * 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
AU745409B2 (en) * 1997-01-29 2002-03-21 Cornell Research Foundation Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
EP1139751A4 (en) * 1998-12-28 2003-03-19 Arch Dev Corp EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050079A2 (en) * 1997-05-06 1998-11-12 The Regents Of The University Of California Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
WO1999040945A2 (en) * 1998-02-11 1999-08-19 The Regents Of The University Of California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544698A (ja) * 2006-07-25 2009-12-17 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
JP2014218509A (ja) * 2006-07-25 2014-11-20 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
CN114173863A (zh) * 2019-08-07 2022-03-11 西北大学 用于在心脏中基因递送的材料和方法
JP2022543622A (ja) * 2019-08-07 2022-10-13 ノースウェスタン ユニバーシティ 心臓内遺伝子送達のための材料及び方法
JP7717677B2 (ja) 2019-08-07 2025-08-04 ノースウェスタン ユニバーシティ 心臓内遺伝子送達のための材料及び方法

Also Published As

Publication number Publication date
KR20020049031A (ko) 2002-06-24
EP1225921A1 (en) 2002-07-31
CA2389524A1 (en) 2001-05-17
NZ546670A (en) 2009-02-28
AU1460401A (en) 2001-06-06
WO2001034208A1 (en) 2001-05-17
EA008538B1 (ru) 2007-06-29
EA200200533A1 (ru) 2002-12-26
HK1048593A1 (zh) 2003-04-11
AU784392B2 (en) 2006-03-23
CN1433325A (zh) 2003-07-30

Similar Documents

Publication Publication Date Title
US20090082293A1 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
AU706908B2 (en) Gene-transfer-mediated angiogenesis therapy
US20080254109A1 (en) Localized myocardial injection method for treating ischemic myocardium
JPH10501423A (ja) 遺伝子転移媒介の血管形成療法
AU784392B2 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
CA2289600C (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
CN100350979C (zh) 核酸和血管活性剂相组合用于加强的基因投递
AU2006200170B2 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU706050C (en) Gene transfer-mediated angiogenesis therapy
HK1094944A (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU2006235836A1 (en) Gene transfer-mediated angiogenesis therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110902